Veracyte, Inc.
NASDAQ:VCYTBiotechnology
+$1.83 today
- Market cap
- $2.06B
- Beta
- 1.98
- P/E (TTM)
- 48.0
- EPS (TTM)
- $1.11
Volume 2.45M
Average 1.05M
VCYT EBITDA Margin
EBITDA as a percentage of revenue.
Veracyte, Inc.NASDAQ: VCYT
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to 16.2%
EBITDA Margin was 16.2% in Q2 FY2026, up 11.0 pp from a year earlier. On a trailing-twelve-month basis it was 23.1%, up 13.6 pp year over year. Over 3 fiscal years it widened by 20.8 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 7 analysts of 36.5% for the fiscal year ending Dec 2026, up from 17.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 16.2%-9.3 pp QoQ
- Last fiscal yearDec 2025
- 17.3%+6.3 pp YoY
- LTMJun 2026
- 23.1%+13.6 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +11.0 pp | +15.0 pp | +4.0 pp |
| 1 year | +6.3 pp | +19.1 pp | +12.8 pp |
| 3 years | +20.8 pp | +13.2 pp | -7.6 pp |
| 5 years | +8.7 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 17.3%
- Year-over-year change
- +6.3pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.3% | +6.3pp |
| FY2024 | 2024-12-31 | 11.0% | +24.7pp |
| FY2023 | 2023-12-31 | -13.7% | -10.2pp |
| FY2022 | 2022-12-31 | -3.5% | +24.7pp |
| FY2021 | 2021-12-31 | -28.2% | — |
EBITDA Margin vs competitors
How VCYT compares with its peers on the latest reported figures
- VCYT's LTM Jun 2026 EBITDA Margin of 23.1% is the highest of the 10 companies compared; the peer median is -19.1%.
- Its year-over-year change of +13.6 pp is the 3rd highest of 10, against a peer median of -12.0 pp.
- Over three fiscal years its change of +20.8 pp compares with a peer median of +98.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 23.1% | +13.6 pp | +20.8 pp | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | 12.6% | +21.8 pp | — |
| LTM Jun 2026 | 1.7% | +5.8 pp | +10.8 pp | |
| LTM Mar 2026 | -0.2% | -12.0 pp | +45.9 pp | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | -16.8% | -24.5 pp | +171.2 pp |
| LTM Mar 2026 | -19.1% | +17.8 pp | +110.1 pp | |
| LTM Sep 2026 | -34.5% | +4.7 pp | +98.7 pp | |
| LTM Mar 2026 | -40.3% | -32.6 pp | -27.6 pp | |
| LTM Mar 2026 | -132.6% | -47.0 pp | — | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -2329.5% | -862.2 pp | +207.6 pp |
| Peer median (excluding VCYT) | -19.1% | -12.0 pp | +98.7 pp | |
Competitors are the stored peer set for VCYT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 219.51M | 296.54M | 361.05M | 445.76M | 517.15M |
| Cost of Revenue | 74.4M | 101.58M | 112.9M | 147.62M | 157.1M |
| Gross Profit | 145.11M | 194.95M | 248.15M | 298.15M | 360.05M |
| Gross Margin | 66.1% | 65.7% | 68.7% | 66.9% | 69.6% |
| Research & Development | 29.84M | 40.6M | 57.31M | 69.29M | 70.81M |
| Selling, General & Admin | 181.19M | 174.08M | 184.23M | 206.04M | 210.95M |
| Operating Expenses | 227.02M | 236.04M | 333.94M | 282M | 285.9M |
| Depreciation & Amortization | 19.59M | 25.93M | 27.19M | 23.46M | 21.42M |
| EBITDA | (61.82M) | (10.3M) | (49.41M) | 49.21M | 89.62M |
| EBITDA Margin | -28.2% | -3.5% | -13.7% | 11.0% | 17.3% |
| Operating Income | (81.9M) | (41.08M) | (85.8M) | 16.14M | 74.15M |
| Operating Margin | -37.3% | -13.9% | -23.8% | 3.6% | 14.3% |
| Interest Income | 135K | 1.97M | 7.34M | 11.15M | 0 |
| Interest Expense | 241K | 198K | 15K | 2K | 0 |
| Other Income / Expenses | 254K | 4.65M | 9.18M | 9.6M | (5.95M) |
| Income Before Tax | (81.65M) | (36.43M) | (76.61M) | 25.74M | 68.2M |
| Pre-Tax Margin | -37.2% | -12.3% | -21.2% | 5.8% | 13.2% |
| Income Tax Expense | (6.09M) | 133K | (2.21M) | 1.61M | 1.85M |
| Net Income | (75.56M) | (36.56M) | (74.4M) | 24.14M | 66.35M |
| Net Margin | -34.4% | -12.3% | -20.6% | 5.4% | 12.8% |
| EPS (Basic) | (1.11) | (0.51) | (1.02) | 0.32 | 0.84 |
| EPS (Diluted) | (1.11) | (0.51) | (1.02) | 0.31 | 0.82 |
| Weighted Avg Shares | 67.89M | 71.55M | 72.64M | 76.48M | 78.58M |
| Weighted Avg Shares (Diluted) | 67.89M | 71.55M | 72.64M | 78.16M | 80.57M |
Veracyte, Inc.
NASDAQ:VCYT
Intrinsic Alpha fair value
Locked
Current Price
$25.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.